Literature DB >> 10846097

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.

S Pepperl1, J Münster, M Mach, J R Harris, B Plachter.   

Abstract

Infection of fibroblast cell cultures with human cytomegalovirus (HCMV) leads to the production of significant amounts of defective enveloped particles, termed dense bodies (DB). These noninfectious structures contain major antigenic determinants which are responsible for induction of both the humoral and the cellular immune response against HCMV. We tested the hypothesis that, by virtue of their unique antigenic and structural properties, DB could induce a significant immune response in the absence of infectious virus. Mice were immunized with gradient-purified DB, which were either left untreated or subjected to sequential rounds of sonication and freeze-thawing to prevent cellular entry. Titers of neutralizing antibodies induced by DB were in a range comparable to levels present in convalescent human sera. The virus-neutralizing antibody response was surprisingly durable, with neutralizing antibodies detected 12 months following primary immunization. The HCMV-specific major histocompatibility complex class I-restricted cytolytic T-cell (CTL) response was assayed using mice transgenic for the human HLA-A2 molecule. Immunization with DB led to high levels of HCMV-specific CTL in the absence of de novo viral protein synthesis. Maximal total cytolytic activity in mice immunized with DB was nearly as efficient as the cytolytic activity induced by a standard immunization with murine cytomegalovirus. Furthermore, DB induced a typical T-helper 1 (Th1)-dominated immune response in mice, as determined by cytokine and immunoglobulin G isotype analysis. Induction of humoral and cellular immune responses was achieved without the concomitant use of adjuvant. We thus propose that DB can serve as a basis for the future development of a recombinant nonreplicating vaccine against HCMV. Finally, such particles could be engineered for efficient delivery of antigens from other pathogens to the immune system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10846097      PMCID: PMC112112          DOI: 10.1128/jvi.74.13.6132-6146.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  85 in total

1.  Resistance of seropositive volunteers to subcutaneous challenge with low-passage human cytomegalovirus.

Authors:  S A Plotkin; R E Weibel; G Alpert; S E Starr; H M Friedman; S R Preblud; J Hoxie
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

2.  Characterization of phosphoproteins and protein kinase activity of virions, noninfectious enveloped particles, and dense bodies of human cytomegalovirus.

Authors:  C Roby; W Gibson
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

Review 3.  Role of cytokines in determining T-lymphocyte function.

Authors:  A O'Garra; K Murphy
Journal:  Curr Opin Immunol       Date:  1994-06       Impact factor: 7.486

4.  Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.

Authors:  E McLaughlin-Taylor; H Pande; S J Forman; B Tanamachi; C R Li; J A Zaia; P D Greenberg; S R Riddell
Journal:  J Med Virol       Date:  1994-05       Impact factor: 2.327

5.  Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes.

Authors:  D M Kranz; S Tonegawa; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties.

Authors:  G Jahn; B C Scholl; B Traupe; B Fleckenstein
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

7.  Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus.

Authors:  B Rüger; S Klages; B Walla; J Albrecht; B Fleckenstein; P Tomlinson; B Barrell
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

8.  CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity.

Authors:  M J Reddehase; W Mutter; K Münch; H J Bühring; U H Koszinowski
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

9.  Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection.

Authors:  M J Reddehase; U H Koszinowski
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

10.  Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice.

Authors:  W Britt; J Fay; J Seals; C Kensil
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

View more
  36 in total

1.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

3.  Modification of the HCMV-specific IFN-γ release test (QuantiFERON-CMV) and a novel proposal for its application.

Authors:  Takahiro Kobayashi; Jun-Ichi Sato; Kazufumi Ikuta; Ryoko Kanno; Kyoko Nishiyama; Tetsuo Koshizuka; Ken Ishioka; Tatsuo Suzutani
Journal:  Fukushima J Med Sci       Date:  2017-06-22

Review 4.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

5.  Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.

Authors:  Christopher S Morello; Ming Ye; Stephanie Hung; Laura A Kelley; Deborah H Spector
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Virus-Like Vesicles of Kaposi's Sarcoma-Associated Herpesvirus Activate Lytic Replication by Triggering Differentiation Signaling.

Authors:  Danyang Gong; Xinghong Dai; Yuchen Xiao; Yushen Du; Travis J Chapa; Jeffrey R Johnson; Xinmin Li; Nevan J Krogan; Hongyu Deng; Ting-Ting Wu; Ren Sun
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06

8.  Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?

Authors:  Mark R Schleiss
Journal:  Future Virol       Date:  2013-12       Impact factor: 1.831

9.  Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83).

Authors:  Alistair McGregor; Fenyong Liu; Mark R Schleiss
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  The Abundant Tegument Protein pUL25 of Human Cytomegalovirus Prevents Proteasomal Degradation of pUL26 and Supports Its Suppression of ISGylation.

Authors:  Christine Zimmermann; Nicole Büscher; Steffi Krauter; Nadine Krämer; Uwe Wolfrum; Elisabeth Sehn; Stefan Tenzer; Bodo Plachter
Journal:  J Virol       Date:  2018-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.